Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 4Stomach Neoplasms 3Triple Negative Breast Neoplasms 2Advanced Solid Tumor 2Advanced Cancer 2Solid Tumor, Adult 1Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1NSCLC 1Mouth Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Cytochrome P450 Interaction 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Biliary Tract Malignancies 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Nivolumab 8Paclitaxel 6Sirolimus 5Bevacizumab 5temsirolimus 4Pemetrexed 4Ipilimumab 4Docetaxel 4Carboplatin 4ARRY-334543 4Gemcitabine 3Erlotinib Hydrochloride 3olaparib 2linrodostat 2apatinib 2anlotinib 2abemaciclib 2Vorinostat 2Sunitinib 2Magnetic Resonance Spectroscopy 2Irinotecan 2Everolimus 2Doxorubicin 2Dasatinib 2Chlorogenic Acid 2Cetuximab 26-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2vorolanib 1vistusertib 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Advanced Cancer × apatinib × Clear all
NCT03645200 2019-04-25

Treatment of Carrying TP53 Harmful Mutations

Tianjin Medical University Second Hospital

Phase 1 Unknown
60 enrolled

Advanced Cancer

NCT03243643 2017-09-08

HS:Hansoh;

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Unknown
80 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡